Pablo Cagnoni

President, Head of Research & Development
Incyte

Pablo J. Cagnoni, M.D., is President, Head of Research & Development at the biopharmaceutical company Incyte. In his role, Dr. Cagnoni oversees Incyte’s research and development efforts across its full portfolio of programs in Hematology, Oncology and Inflammation and Autoimmunity.

Prior to joining Incyte, Dr. Cagnoni served as the Chief Executive Officer of Laronde, a company dedicated to the development of a new type of translatable ribonucleic acid (RNA) called endless RNA (eRNA), and held leadership roles at Rubius Therapeutics, Tizona Therapeutics, Onyx Pharmaceuticals and Novartis Oncology. Throughout his career as a pharmaceutical executive and oncologist, Dr. Cagnoni has advanced the development of breakthrough treatments, playing a key role in the development, approval and commercialization of more than 20 life-changing medicines.

Dr. Cagnoni earned his medical degree from the University of Buenos Aires School of Medicine. He completed his fellowship in Hematology and Oncology at the Mount Sinai Medical Center, New York, and a fellowship in Stem Cell Transplantation at the University of Colorado Health Sciences Center.